2026 drug price negotiations by the Biden administration aim to save Medicare recipients $1.5 billion on out-of-pocket costs.

The Biden administration's new drug price negotiations with pharmaceutical companies starting in 2026 aim to save Medicare recipients $1.5 billion on out-of-pocket costs for medications treating diabetes, heart disease, blood cancers, and other conditions. These savings include a 79% reduction for Januvia, a diabetes drug, and a 38% decrease for Imbruvica, used for blood cancers. The figures refer to the drug's cost before any discounts or rebates, not the actual amount paid by patients.

August 18, 2024
26 Articles